Renal physiology

CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration

Retrieved on: 
Thursday, September 10, 2020
Renal physiology, Ultrafiltration, Hypervolemia

Clinically important observations made by Dr. Jefferies during the webinar include:

Key Points: 
  • Clinically important observations made by Dr. Jefferies during the webinar include:
    The impact of fluid overload on HF patients is significant.
  • There are many patients who can benefit from ultrafiltration therapy and this educational webinar helps to ensure providers are equipped with knowledge of various treatment options for fluid overloaded patients.
  • Access this information and a white paper analysis by watching the webinar replay available on the company website and on CHF Solutions YouTube page .
  • CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation.

North America Creatinine Measurement Market, 2020-2027: COVID-19 Impact and Regional Analysis by Product, Type, Sample Type, & End-User - ResearchAndMarkets.com

Retrieved on: 
Monday, September 7, 2020
Managed care, General Health, Health, Other Health, Guanidines, Branches of biology, Renal physiology, Creatinine, Metabolism, Anatomy, Biology, Creatine

The "North America Creatinine Measurement Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product; Type; Sample Type; End-User, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Creatinine Measurement Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product; Type; Sample Type; End-User, and Country" report has been added to ResearchAndMarkets.com's offering.
  • The North American Creatinine Measurement Market is expected to reach US$ 269.75 million in 2027 from US$ 148.79 million in 2019.
  • The growth of the creatinine measurement market is attributed to the increasing prevalence of chronic kidney disorders, growing geriatric population, and others.
  • Thus, technological factors are likely to foster the growth of the North America creatinine measurement market during the forecast period.

FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial

Retrieved on: 
Sunday, August 30, 2020
Research, Diabetes, Clinical trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Science, Medical specialties, Anatomy, Kidney diseases, Branches of biology, Anti-diabetic drugs, Organ failure, Blood tests, Renal physiology, SGLT2 inhibitor, Sodium-glucose transport proteins, Acute kidney injury, Chronic kidney disease

The primary composite endpoint was 50% sustained decline in estimated glomerular filtration rate (eGFR), onset of end stage kidney disease (ESKD) and CV or renal death.

Key Points: 
  • The primary composite endpoint was 50% sustained decline in estimated glomerular filtration rate (eGFR), onset of end stage kidney disease (ESKD) and CV or renal death.
  • The trial also met all secondary endpoints, including significantly reducing death from any cause by 31% (ARR = 2.1%, p=0.0035) compared to placebo.
  • In the trial, patients treated with FARXIGA experienced fewer serious adverse events compared to placebo (29.5% versus 33.9%, respectively).
  • Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors, including FARXIGA.

DGAP-News: SphingoTec's kidney function biomarker penKid(R) accurately detects acute kidney injury in infants

Retrieved on: 
Thursday, August 27, 2020
Branches of biology, Anatomy, Clinical medicine, Kidney diseases, Blood tests, Renal physiology, Organ failure, Acute kidney injury, Biomarker, Glomerular filtration rate, Kidney, Assessment of kidney function

Hennigsdorf/Berlin, Germany, August 27, 2020 - Diagnostics company SphingoTec GmbH ("SphingoTec") announced today the publication of first data (1), proving that its real-time kidney function biomarker penKid(R) is a reliable biomarker for the diagnosis of acute kidney injury (AKI) in infants.

Key Points: 
  • Hennigsdorf/Berlin, Germany, August 27, 2020 - Diagnostics company SphingoTec GmbH ("SphingoTec") announced today the publication of first data (1), proving that its real-time kidney function biomarker penKid(R) is a reliable biomarker for the diagnosis of acute kidney injury (AKI) in infants.
  • (1) Hartman et al (2020), Proenkephalin as a New Biomarker for Pediatric Acute Kidney Injury - Reference Values and Performance in Children Under One Year of Age, Clin Chem Lab Med, doi: 10.1515/cclm-2020-0381 .
  • penKid(R) has been demonstrated to be a real-time surrogate biomarker for glomerular filtration rate, the gold standard to assess renal function.
  • Measuring penKid(R) blood concentrations allows for timely information on kidney function in critically ill patients.

Global Ultrafiltration Industry

Retrieved on: 
Wednesday, August 26, 2020
Renal physiology, Ultrafiltration

US Ultrafiltration Market Share (in %) by Company: 2019 & 2025

Key Points: 
  • US Ultrafiltration Market Share (in %) by Company: 2019 & 2025
    Projections in US$ Thousand by Type: 2020 to 2027
    Table 23: Ultrafiltration Market in the United States by Type:
    Projections in US$ Thousand by Module: 2020 to 2027
    in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Type: 2020 to 2027
    Breakdown of Sales by Type for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Module: 2020 to 2027
    Breakdown of Sales by Module for 2012, 2020, and 2027
    Analysis in US$ Thousand by Application: 2020 to 2027
    Ultrafiltration in US$ Thousand by Application: 2020 to 2027
    Table 51: Chinese Ultrafiltration Market by Type: Percentage
    Breakdown of Sales for 2012, 2020, and 2027
    Table 54: Chinese Ultrafiltration Market by Module: Percentage
    Breakdown of Sales for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Type: 2020-2027
    Forecasts in US$ Thousand by Module: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 70: Ultrafiltration Market in France by Type: Estimates
    Table 72: French Ultrafiltration Market Share Analysis by Type:
    Table 73: Ultrafiltration Market in France by Module: Estimates
    France in US$ Thousand by Application: 2020-2027
    Table 78: French Ultrafiltration Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Table 90: Italian Ultrafiltration Market by Type: Percentage
    Breakdown of Sales for 2012, 2020, and 2027
    Table 93: Italian Ultrafiltration Market by Module: Percentage
    Breakdown of Sales for 2012, 2020, and 2027
    Table 97: United Kingdom Market for Ultrafiltration: Annual
    Table 98: Ultrafiltration Market in the United Kingdom:
    Table 100: United Kingdom Market for Ultrafiltration: Annual
    Table 101: Ultrafiltration Market in the United Kingdom:
    Ultrafiltration in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Type: 2020 to 2027
    Breakdown of Sales by Type for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Module: 2020 to 2027
    Breakdown of Sales by Module for 2012, 2020, and 2027
    Analysis in US$ Thousand by Application: 2020 to 2027
    Projections in US$ Thousand by Type: 2020 to 2027
    Table 116: Ultrafiltration Market in Russia by Type: A Historic
    Projections in US$ Thousand by Module: 2020 to 2027
    Table 119: Ultrafiltration Market in Russia by Module:
    Forecasts in US$ Thousand by Type: 2020-2027
    Forecasts in US$ Thousand by Module: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 131: Ultrafiltration Market in Rest of Europe:
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Table 136: Ultrafiltration Market in Asia-Pacific by Type:
    Scenario in US$ Thousand by Type: 2012-2019
    Table 139: Ultrafiltration Market in Asia-Pacific by Module:
    Scenario in US$ Thousand by Module: 2012-2019
    Asia-Pacific in US$ Thousand by Application: 2020-2027
    in US$ Thousand by Application: 2012-2019
    Table 144: Asia-Pacific Ultrafiltration Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    in US$ Thousand by Type: 2012-2019
    in US$ Thousand by Module: 2012-2019
    Forecasts in US$ Thousand by Type: 2020 to 2027
    Breakdown of Sales by Type for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Module: 2020 to 2027
    Breakdown of Sales by Module for 2012, 2020, and 2027
    Analysis in US$ Thousand by Application: 2020 to 2027
    Table 163: Ultrafiltration Market in South Korea: Recent Past,
    Analysis in US$ Thousand by Type: 2012-2019
    Table 166: Ultrafiltration Market in South Korea: Recent Past,
    Analysis in US$ Thousand by Module: 2012-2019
    Table 169: Ultrafiltration Market in South Korea: Recent Past,
    Analysis in US$ Thousand by Application: 2012-2019
    Table 172: Rest of Asia-Pacific Market for Ultrafiltration:
    Table 173: Ultrafiltration Market in Rest of Asia-Pacific:
    Table 175: Rest of Asia-Pacific Market for Ultrafiltration:
    Table 176: Ultrafiltration Market in Rest of Asia-Pacific:
    for Ultrafiltration in US$ Thousand by Application: 2020 to
    Breakdown of Sales by Region/Country: 2012, 2020, and 2027
    America in US$ Thousand by Type: 2012-2019
    Table 186: Latin American Ultrafiltration Market by Type:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    America in US$ Thousand by Module: 2012-2019
    Table 189: Latin American Ultrafiltration Market by Module:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Type: 2020-2027
    Forecasts in US$ Thousand by Module: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 202: Ultrafiltration Market in Brazil by Type: Estimates
    in US$ Thousand by Type: 2012-2019
    Table 205: Ultrafiltration Market in Brazil by Module:
    in US$ Thousand by Module: 2012-2019
    Brazil in US$ Thousand by Application: 2020-2027
    Table 210: Brazilian Ultrafiltration Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Estimates and Projections in US$ Thousand by Type: 2020 to 2027
    Estimates and Projections in US$ Thousand by Module: 2020 to
    Forecasts in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Forecasts in US$ Thousand by Type: 2020 to 2027
    Table 234: Ultrafiltration Market in the Middle East:
    Percentage Share Breakdown of Sales by Type for 2012,2020, and
    Forecasts in US$ Thousand by Module: 2020 to 2027
    Table 237: Ultrafiltration Market in the Middle East:
    Percentage Share Breakdown of Sales by Module for 2012,2020,
    Demand Analysis in US$ Thousand by Application: 2020 to 2027
    Table 239: Ultrafiltration Market in the Middle East:
    Ultrafiltration in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Type: 2020-2027
    Forecasts in US$ Thousand by Module: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Arabia in US$ Thousand by Type: 2012-2019
    Table 261: Saudi Arabian Ultrafiltration Market by Type:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Arabia in US$ Thousand by Module: 2012-2019
    Table 264: Saudi Arabian Ultrafiltration Market by Module:
    ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX

Retrieved on: 
Wednesday, August 26, 2020
Anatomy, Kidney diseases, Medical specialties, Chronic kidney disease, Organ failure, RTT, Branches of biology, Blood tests, Renal physiology, Artificial kidney, Assessment of kidney function

In May 2019, RenalytixAI announced that KidneyIntelX was granted Breakthrough Device designation by FDA, the first such designation for an artificial intelligence-enabled in vitro diagnostic for kidney disease publicly announced by any company.

Key Points: 
  • In May 2019, RenalytixAI announced that KidneyIntelX was granted Breakthrough Device designation by FDA, the first such designation for an artificial intelligence-enabled in vitro diagnostic for kidney disease publicly announced by any company.
  • Patients with CKD and type 2 diabetes account for 20-30 percent of the estimated 37 million U.S. patients with CKD2.
  • RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally.
  • Examples of these forward-looking statements include statements concerning: our ability to achieve regulatory clearance of KidneyIntelX from the FDA and the ability of KidneyIntelX to curtail costs of CKD and end-stage kidney disease and improve patient outcomes.

Insights into the Global Creatinine Measurement Market to 2027 - Analysis and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 18, 2020
General Health, Health, Fitness & Nutrition, Guanidines, Branches of biology, Renal physiology, Creatinine, Metabolism, Biology, Kidney diseases, Creatine, Assessment of kidney function, Glomerular filtration rate

The "Creatinine Measurement Market to 2027 - Global Analysis and Forecasts by Product; Type; Sample Type; End-User, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Creatinine Measurement Market to 2027 - Global Analysis and Forecasts by Product; Type; Sample Type; End-User, and Country" report has been added to ResearchAndMarkets.com's offering.
  • Factors driving the creatinine measurement market are increasing prevalence of chronic kidney disorders (CKD) and growing prevalence of CKD among the geriatric population.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the creatinine measurement market.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

CHF Solutions to Host Webinar Discussing Fluid Management Strategies in Critically Ill COVID-19 Patients

Retrieved on: 
Friday, June 12, 2020
Medicine, Anatomy, Branches of biology, Organ failure, Membrane technology, Renal physiology, Ultrafiltration, RTT, Kidney, Hypervolemia, Aquapheresis, Dialysis

When the kidneys cannot remove the excess fluid and waste in the body, these patients can experience kidney failure and multi-organ failure.

Key Points: 
  • When the kidneys cannot remove the excess fluid and waste in the body, these patients can experience kidney failure and multi-organ failure.
  • Effective fluid management in critically ill COVID patients can help prevent AKI and mitigate devastating outcomes in these patients.
  • Isolated ultrafiltration is an optimal strategy that primarily focuses on fluid extraction and management of fluid volume.
  • Portable ultrafiltration devices are proving particularly helpful in critically ill COVID-19 patients because the extremely small extracorporeal volume (i.e.

CHF Solutions Announces the Launch of Pediatric Ultrafiltration Therapy Using the Aquadex SmartFlow System at Children’s Hospital of The King’s Daughters

Retrieved on: 
Thursday, June 4, 2020
Membrane technology, Chemistry, Natural sciences, Physical sciences, Water treatment, Renal physiology, Ultrafiltration, Hypervolemia

EDEN PRAIRIE, Minn., June 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced Childrens Hospital of The Kings Daughters (CHKD) in Norfolk, Virginia has initiated ultrafiltration therapy using the Aquadex SmartFlow system.

Key Points: 
  • EDEN PRAIRIE, Minn., June 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced Childrens Hospital of The Kings Daughters (CHKD) in Norfolk, Virginia has initiated ultrafiltration therapy using the Aquadex SmartFlow system.
  • Following FDA clearance and the launch of the Aquadex SmartFlow system in the first quarter, we continue to see strong interest from pediatric hospitals, said John Erb, chairman and CEO of CHF Solutions.
  • We are proud to work with the medical team at Childrens Hospital of The Kings Daughters to bring this simple, gentle and smart therapy to its patients suffering from fluid overload.
  • The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy.

Publication Highlights Use of Ultrafiltration for Fluid Management in COVID-19 Patients

Retrieved on: 
Wednesday, May 20, 2020
Medicine, Branches of biology, Renal physiology, Ultrafiltration, Clinical medicine, Hypervolemia, Intravascular volume status, Membrane technology, Aquapheresis

EDEN PRAIRIE, Minn., May 20, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a publication highlighting the use of ultrafiltration for fluid management of critically ill patients suffering from COVID-19.

Key Points: 
  • EDEN PRAIRIE, Minn., May 20, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a publication highlighting the use of ultrafiltration for fluid management of critically ill patients suffering from COVID-19.
  • SARS-CoV-2 (COVID-19) and Intravascular Volume Management Strategies in the Critically Ill1 calls attention to fluid stewardship in COVID-19 patients by judiciously applying the evidence-based resuscitation principles to the specific clinical features of COVID-19 patients.
  • Highlights of ultrafiltration identified in the publication include:
    Isolated ultrafiltration is an optimal strategy that primarily focuses on fluid extraction and optimization of volume status;
    Portable ultrafiltration devices could prove particularly helpful because the extremely small extracorporeal volume (i.e.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.